APA (7th ed.) Citation

Shen, Y., Mushti, S., Mulkey, F., Gwise, T., Wang, X., Zhou, J., . . . Sridhara, R. (2023). Rejoinder to Comments on "Non-Proportional Hazards – An Evaluation of the MaxCombo Test in Cancer Clinical Trials". Statistics in Biopharmaceutical Research, 15(2), 315. https://doi.org/10.1080/19466315.2023.2203007

Chicago Style (17th ed.) Citation

Shen, Yuan-Li, et al. "Rejoinder to Comments on "Non-Proportional Hazards – An Evaluation of the MaxCombo Test in Cancer Clinical Trials"." Statistics in Biopharmaceutical Research 15, no. 2 (2023): 315. https://doi.org/10.1080/19466315.2023.2203007.

MLA (9th ed.) Citation

Shen, Yuan-Li, et al. "Rejoinder to Comments on "Non-Proportional Hazards – An Evaluation of the MaxCombo Test in Cancer Clinical Trials"." Statistics in Biopharmaceutical Research, vol. 15, no. 2, 2023, p. 315, https://doi.org/10.1080/19466315.2023.2203007.